{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-25-000029","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.675882+00:00","generated_at":"2026-05-24T21:27:15.770670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rallybio Q4 net loss $11M, cash $65.5M; key trial data readouts in 2025","bullets":["Q4 2024 net loss $11.0M ($0.25/share) vs $20.2M ($0.50/share) in Q4 2023; full-year loss $57.8M.","Revenue $38k in Q4 2024 from J&J collaboration; zero revenue in year ago period.","Cash, equivalents, and marketable securities $65.5M as of Dec 31, 2024; runway into 2H 2026.","RLYB212 Phase 2 sentinel participant dosed; PK/safety data from 2nd trimester expected Q2 2025, at delivery Q3 2025.","RLYB116 confirmatory PK/PD study to start Q2 2025; Cohorts 1 and 2 data in Q3/Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-25-000029","json":"https://secwatch.observer/filing/0001739410-25-000029.json","markdown":"https://secwatch.observer/filing/0001739410-25-000029.md","text":"https://secwatch.observer/filing/0001739410-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/0001739410-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:27:15.770670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}